H.R. 2276 (112th): To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes.

Introduced:
Jun 22, 2011 (112th Congress, 2011–2013)
Status:
Died (Referred to Committee)
Sponsor
Debbie Wasserman Schultz
Representative for Florida's 20th congressional district
Party
Democrat
Text
Read Text »
Last Updated
Jun 22, 2011
Length
3 pages
Related Bills
H.R. 1249 (Related)
Leahy-Smith America Invents Act

Signed by the President
Sep 16, 2011

 
Status

This bill was introduced on June 22, 2011, in a previous session of Congress, but was not enacted.

Progress
Introduced Jun 22, 2011
Referred to Committee Jun 22, 2011
 
Summary

No summaries available.

Cosponsors
none
Committees

House Energy and Commerce

Health

House Judiciary

Intellectual Property, Competition, and the Internet

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


6/22/2011--Introduced.
Directs the Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO) to: (1) study ways to provide independent, confirming genetic diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic tests exist; and (2) report the findings to Congress within nine months along with recommendations for establishing the availability of such independent confirming genetic diagnostic test activity.
Defines “confirming genetic diagnostic test activity” as the performance of a genetic diagnostic test, by a genetic diagnostic test provider, on an individual solely for the purpose of providing the individual with an independent confirmation of results obtained from another test provider’s prior performance of the test on the individual.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 2276 (112th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus